Concepedia

Klemens Lustig

KL

Statistics

Publications

14

Citations

665

H-Index

13

Active since

1993

Affiliations

Bayer (Germany)(Current)

Bayer (United States)

Klemens Lustig is an author at Bayer (Germany) specializing in pharmacology, drug discovery, and pharmacy.

Publications per year

1993–2020

14

Publications

14

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

Markus Follmann, Jens Ackerstaff, Gorden Redlich et al. · Journal of Medicinal Chemistry · 2017 · 197 citations · Full text

, , +17

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Sylvia Grünewald, Oliver Politz, Sebastian Bender et al. · International Journal of Cancer · 2019 · 101 citations · Full text

, , +16

Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling

Stephan Schäfer, Peter Ellinghaus, Wiebke Janssen et al. · Cardiovascular Research · 2009 · 70 citations · Full text

, , +17

Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85‐8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases

Franz von Nussbaum, Volkhart M.‐J. Li, Swen Allerheiligen et al. · ChemMedChem · 2015 · 67 citations · Full text

, , +17

Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor

Marie-Pierre L. Collin, Mario Lobell, Walter Hübsch et al. · ChemMedChem · 2018 · 62 citations

, , +17

1–5 of 14